CASI
CASI Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.15
+3.08%Year over year
Reported trailing growth
- Revenue
- +21.7%
- EBITDA
- -48.4%
- EBIT
- -44.5%
- EPS
- -41.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -1.8%
- EBITDA
- -61.9%
- EBIT
- -58.0%
- Net income
- -45.7%
- EPS
- -26.7%
- Free cash flow
- -32.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025